PDUFA V Focus On Speeding FDA Drug Reviews May Be Unfounded, Study Concludes
Executive Summary
A New England Journal of Medicine study found that FDA is faster in reviewing novel therapeutics than regulatory agencies in Europe and Canada.
You may also be interested in...
FDA/EMA Review Discord: Is Europe Slow On Oncology, Or Just Fast On Everything Else?
Tufts study finds that FDA approves oncology drugs in seven months and non-oncology drugs in 17 months; European Medicines Agency approval times are 27% shorter for non-oncology drugs and 54% longer for oncology therapeutics compared to FDA.
Lorcaserin Safety Questions Can Be Answered In Post-Market Study, Panel Tells FDA
FDA’s Endocrinologic and Metabolic Advisory Committee backs approval of Arena’s weight-loss drug 18 to 4 with one abstention. Uncertainty over the risk for heart disease remains a prime concern for panel members.
CV Risk Assessment For All Obesity Drugs Seems Inevitable Pre-Approval Requirement
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee March 29 voted 17-6 that all obesity drugs should be vetted for cardiovascular risk, but some could rely on a meta-analysis rather than an outcomes trial.